drugset / Trial / NCT02342184
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This study will carry out to assess the efficacy of GB-0998 (intravenous immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome based on the changes in Hughes Functional Grade (FG) as primary endpoint, and in addition, to assess the safety of GB-0998.
Timeline
- Start
- 2014-08
- Primary completion
- 2015-09
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GB-0998 | Protein / enzyme biologic | 400 mg/kg | Intravenous |